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Summary 
Background Salmonella enterica serotype Typhi (S Typhi) is a major public health problem in low-income and middle-
income countries. We aimed to investigate the effectiveness and impact of the typhoid conjugate vaccine Typbar-TCV 
against S Typhi among children in an outbreak setting of extensively drug-resistant (XDR) S Typhi in Pakistan.
Methods This cohort study was done from Feb 21, 2018, to Dec 31, 2019. A census survey of all households located in 
the Qasimabad and Latifabad subdistricts of Hyderabad, Pakistan, was done at baseline, and 174 005 households were 
registered in the census. The Typbar-TCV immunisation campaign was initiated at temporary vaccination centres and 
207 000 children aged 6 months to 10 years were vaccinated from Feb 21, 2018, to Dec 31, 2018. Social mobilisers 
informed parents about the vaccination process. Vaccination records were maintained electronically and linked with 
the household census surveys. Active surveillance for suspected and blood-culture-confirmed S Typhi was established 
in hospitals, clinics, and laboratories to assess the following outcomes: cases of suspected typhoid fever, culture-
confirmed S Typhi, and antimicrobial resistance. An age-stratified cohort of 1100 vaccinated children was randomly 
selected from the vaccination registry, tested for Vi-IgG antibodies (data not reported), and followed up fortnightly (via 
telephone calls or household visits) until Dec 31, 2019, for ascertainment of outcomes during the study period. 
20 847 vaccinated and unvaccinated children were randomly selected from the census registry as a quality control 
cohort and followed up from Oct 1 to Dec 31, 2019, for ascertainment of outcomes. Vaccine effectiveness against 
suspected, culture-confirmed, and XDR S Typhi was calculated.
Findings 23 407 children from the census registry and surveillance system were included in the vaccine effectiveness 
analysis. 13 436 (57·4%) children were vaccinated, 12 214 (52·2%) were male, and 10 168 (43·4%) were aged 
6–59 months. 5378 (23·0%) of 23 407 children had suspected S Typhi, among whom 775 (14·4%) had culture-
confirmed S Typhi and 361 (68·6%) of 526 had XDR S Typhi. Vaccine effectiveness was 55% (95% CI 52–57) against 
suspected S Typhi (regardless of culture confirmation), 95% (93–96) against culture-confirmed S Typhi, and 
97% (95–98) against XDR S Typhi.
Interpretation Typbar-TCV is effective in protecting children against S Typhi infection in an outbreak setting, and was 
able, with moderate deployment, to curtail a major XDR S Typhi outbreak in a densely populated setting. The vaccine 
shows efficacy against S Typhi irrespective of antimicrobial resistance.
Funding Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Typhoid fever is a serious public health issue in low-
income and middle-income countries across Africa and 
south Asia. More than 90% of the morbidity and mortality 
related to enteric fever occurs in Asia, predominantly 
among children aged younger than 15 years. In addition 
to the high disease burden of typhoid fever, multidrug 
resistance (resistance or intermediate resistance to 
ampicillin, chloramphenicol, and co-trimoxazole) and 
extensive drug resistance (multidrug resistance along 
with resistance to fluoroquinolone and third-generation 
cephalosporins)1–3 to Salmonella enterica serotype Typhi 
(S Typhi) are a growing threat.3
S Typhi is mainly acquired from contaminated water, 
which is now a ubiquitous challenge in many regions 
as a result of rapid urbanisation. Another important 
source is person-to-person transmission through 
food handlers, especially chronic carriers of S Typhi.4 
Improvements in water and sanitation infrastructure 
and in food safety require major investments, but at 
present there is little imminent progress anticipated 
within these domains in endemic countries. Vaccination 
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against S Typhi therefore offers the best approach for 
disease control.
Older typhoid vaccines, including a single dose of 
the intramuscular Vi-polysaccharide and three-dose oral 
Ty21a vaccine, have suboptimal efficacy, a short duration 
of protection, and cannot be administered to children 
younger than 2 years.5,6 However, the new typhoid 
conjugate vaccine (Typbar-TCV; Bharat Biotech Inter-
national; Hyderabad, India) has shown promising efficacy 
in phase 2b and phase 3 trials.7,8 Moreover, it can be given 
to children from 6 months of age and is prequalified by 
WHO.9 A human challenge study of Typbar-TCV among 
adult volunteers in the UK reported a vaccine efficacy of 
54·6% against S Typhi bacteraemia.7 The results of the 
phase 3 trial of Typbar-TCV in Nepal showed a vaccine 
efficacy of 81·6% in children aged 9 months to 16 years.8 
However, population-based observational studies are 
urgently needed to estimate the effectiveness of Typbar-
TCV in settings with antimicrobial resistance.
In November, 2016, the Aga Khan University Hospital, 
Karachi, Pakistan, identified an emergent extensively 
drug-resistant (XDR) S Typhi outbreak in Hyderabad, 
Pakistan.10 A large-scale vaccination campaign was 
initiated to interrupt transmission. We aimed to 
determine the public health impact and effectiveness 
of Typbar-TCV in preventing blood-culture-confirmed 
S Typhi in children aged 6 months to 10 years, living in 
the outbreak areas of Hyderabad, Pakistan.
Methods
Study design and setting
This cohort study was done from Feb 21, 2018, to 
Dec 31, 2019, in the Qasimabad and Latifabad subdistricts 
of Hyderabad, Pakistan. The total population of 
Hyderabad is around 2·2 million, with 44% of the 
population (977 000) living in these two subdistricts.10 
Hyderabad is composed of a mixture of a middle-class 
and high-density urban slum population. Details of the 
study setting have been published,11 and details of the 
study are summarised in figure 1.
Baseline census and surveillance
We did a census survey of all households located in 
the Qasimabad and Latifabad subdistricts of Hyderabad. 
Each household was assigned a unique identifier. 
On the day of the visit, global positioning system 
(GPS) coordinates and the number, names, sex, and date 
of birth of children aged 6 months to 10 years living in 
each household and the name of the head of the 
household were recorded. Each child was assigned a 
unique identifier. Households located in apartments 
or resi dential compounds were assigned a single GPS 
coordinate. Non-responsive households were revisited 
at the end of the day or a catch-up visit was made on the 
following day. Following these attempts, non-responding 
households were assigned an identifier and GPS 
coordinates, and coded as locked or non-responding. 
Research in context
Evidence before this study
We did an advanced literature search on PubMed and Google 
Scholar using the key terms “TCV” OR “typhoid conjugate 
vaccine” OR “Typbar-TCV” OR “typhoid vaccine” AND 
“effectiveness” OR “impact” OR “efficacy” for studies published 
up to May 30, 2020. Studies unrelated to the typhoid 
conjugate vaccine were excluded. A double-blind, placebo-
controlled, randomised trial of the typhoid conjugate vaccine 
Vi-rEPA (Vi bound to non-toxic recombinant Pseudomonas 
aeruginosa exotoxin A) in children aged 2–5 years in Vietnam 
reported that two doses of the vaccine had a protective efficacy 
of 91·5% (95% CI 77·1–96·6) against culture-confirmed 
Salmonella enterica serotype Typhi (S Typhi) at 27 months; 
however, this vaccine is not prequalified by WHO. Typbar-TCV is 
the only typhoid conjugate vaccine prequalified by WHO. 
A phase 3 randomised controlled trial of Typbar-TCV in Nepal 
reported a 1-year protective efficacy of 82% with a single dose 
of the vaccine in children aged 9 months to 16 years. However, 
more studies are needed to establish the real-world impact and 
effectiveness of Typbar-TCV—ie, as part of a population-based 
immunisation campaign in an outbreak setting.
Added value of this study
In this cohort study, we found that a single dose of Typbar-
TCV was highly effective (vaccine effectiveness >90%) against 
culture-confirmed drug-resistant and culture-sensitive 
S Typhi in children aged 6 months to 10 years in a population-
wide campaign setting in Hyderabad, Pakistan. Mass 
immunisation with Typbar-TCV resulted in a significant 
reduction in culture-confirmed S Typhi cases during the peak 
monsoon seasons of 2018 and 2019, demonstrating the 
impact of vaccination in protecting against increased 
community transmission of S Typhi during the peak 
monsoon season.
Implications of all the available evidence
Typbar-TCV is effective against culture-confirmed S Typhi in 
children aged 6 months to 10 years in an outbreak setting in 
Pakistan and, with only moderate deployment, was able to 
curtail an extensively drug-resistant S Typhi outbreak in a 
densely populated setting. The vaccine is effective against 
S Typhi irrespective of antimicrobial resistance. Typbar-TCV 
can therefore be an important tool to control drug-resistant 
S Typhi outbreaks. Furthermore, on the basis of these 
findings, incorporation of Typbar-TCV into routine 
immunisation programmes in endemic countries is highly 
recommended.
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174 005 households were registered in the census. This 
census registry served as the data frame linking all 
subsequent records from the other components of the 
study, including Typbar-TCV vaccination status during 
the immunisation campaign, and the surveillance 
system.
A detailed description of the surveillance system 
and case definition for suspected and culture-confirmed 
S Typhi has been published.12,13 Briefly, we established 
active surveillance for identification of suspected and 
blood-culture-confirmed S Typhi at 13 sentinel sites, in 
all major hospitals and clinics of general practitioners 
(GPs) in the two subdistricts. Patients presenting to these 
sentinel sites with persistent fever for 3 or more days 
without any focus of infection were considered to have 
suspected typhoid fever, whereas those with a positive 
blood culture for S Typhi were recorded as having 
culture-confirmed S Typhi infection. Training on case 
definitions, the target population, and details of the 
study was provided to at least one focal physician at 
each sentinel site. A trained research assistant visited 
each facility daily to ensure cases were not missed. 
Patients with suspected S Typhi were offered free blood 
culture testing at the nearest Aga Khan University 
Hospital clinical laboratory collection point in Hyderabad, 
Pakistan. We also included cases of culture-confirmed 
S Typhi from two major laboratories in Hyderabad: the 
clinical laboratory of Aga Khan University Hospital and 
that of Liaquat University of Medical Health Sciences, 
Hyderabad, Pakistan. The surveillance system captures 
the whole population of Latifabad and Qasimabad.
Participants and procedures
We began a population-based immunisation cam-
paign using Typbar-TCV in children aged 6 months to 
10 years living in Qasimabad and Latifabad. All eligible 
children were offered free, voluntary vaccination, 
and 207 000 children were vaccinated at temporary 
vaccination centres from Feb 21, 2018, to Dec 31, 2018.11 
With every vaccine dose administered, we recorded the 
recipient’s name, age or date of birth (or both), sex, 
household and child identifier, date of vaccination, 
injection site, vial batch number, and history of previous 
typhoid vaccination. The immuni sation record was 
linked to the baseline census registry through unique 
household and child identifiers.
We randomly selected an age-stratified subcohort 
of 1100 vaccinated children and followed them up from 
the day of vaccination until Dec 31, 2019. We used 
systematic random sampling with replacement to select 
every fifth child in each age group (150 children each 
aged 6–11 months, 12–23 months, 24–35 months, 
36–47 months, and 48–59 months, and 70 children each 
aged 60–71 months, 72–83 months, 84–95 months, 
96–107 months, and 108–120 months) visiting the tem-
porary vaccination centres. This cohort was periodically 
followed up (at 28–42 days, 6 months, 1 year, and 2 years) 
for serial measurement of serum antibody concen-
trations against S Typhi Vi-IgG (data not reported), and 
fortnightly telephone calls were made by the research 
assistants to enquire about history of illness, including 
fever or admission to hospital, or both, during the past 
2 weeks. Data on the immunogenicity of Typbar-TCV 
will be published at a later date, once all blood samples 
have been analysed for Vi-IgG concentrations. Where 
febrile illness was identified, the research medical 
officer visited the household to examine the child and 
collect further clinical details, a hospital discharge 
summary, and laboratory tests (if available), and to 
establish whether the child fulfilled the case definition 
for suspected typhoid fever or culture-con firmed 
S Typhi. Any child with a fever for 3 or more days at 
the time of the telephone call was provided free blood 
culture testing at the nearest Aga Khan University 
Hospital clinical laboratory collection point. Cases were 
cross-checked with surveillance data to avoid duplicates.
We randomly selected another quality control cohort of 
20 847 children using simple random sampling without 
replacement from the baseline census and followed 
them up until Dec 31, 2019. From Oct 1 to Dec 31, 2019, 
trained research assistants visited the households to 
interview parents and collect information about the 
history of fever, suspected typhoid fever, and laboratory 
testing for S Typhi (blood culture, Typhidot), and 
hospital admissions from the date of baseline census or 
Typbar-TCV vaccination until the date of the interview. 
Information about age, sex, and vaccination status was 
available from the census registry. Information about 
laboratory testing, prescriptions or hospital discharge 
Figure 1: Study flow diagram
S Typhi=Salmonella enterica serotype Typhi. Participants were followed up from the date of the census survey or 
vaccination until Dec 31, 2019.
174 005 households (with 222 100 eligible children aged 6 months to 10 years) 
identified in baseline census of Qasimabad and Latifabad (Hyderabad, 
Pakistan); 207 000 children vaccinated with Typbar-TCV 
23 407 children included in vaccine effectiveness analysis
 
20 090 children included in 
vaccine effectiveness 
analysis: 3047 
suspected cases and 
99 culture-confirmed 
positive cases of S Typhi
757 lost to follow-up 42 lost to follow-up
1058 children included in 
vaccine effectiveness 
analysis: 72 suspected 
cases and no 
culture-confirmed 
positive cases of S Typhi
20 847 children in quality 
control cohort
1100 children in vaccinated 
subcohort for intensive 
follow-up
2259 children identified from 
sentinel and laboratory 
surveillance:
1583 suspected cases and 
676 culture-confirmed 
positive cases of S Typhi
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summary (if available), or both, was also recorded. 
Cases were cross-checked with surveillance system 
records to remove any duplicates. Cases were defined as 
suspected typhoid fever or culture-confirmed S Typhi on 
the basis of clinical diagnosis by clinicians working at 
the sentinel hospitals or, where applicable, laboratory 
confirmation of blood cultures. The quality control 
cohort thus provided evidence that cases of suspected 
typhoid fever and culture-confirmed S Typhi were not 
missed as outcomes by the surveillance system.
We developed an electronic data capture programme 
using Java structured query language (SQL) platforms as 
a database for real-time data collection. Data were synced 
to a central server at the Aga Khan University. Dedicated 
staff (NUR and RA) carried out quality assurance and 
quality control checks to identify illogical responses 
and a weekly quality assurance and quality control 
report was provided to the research supervisor (SK) in 
Hyderabad for field verification. Children who were 
missed during the baseline census were assigned new 
registration numbers whenever they were encountered 
by field staff, and their records were assigned to their 
respective household identifier. We linked datasets 
from the typhoid surveillance, vaccinated cohort, quality 
control cohort, and vaccination registry with the baseline 
census using the household identifier and children’s 
unique identifiers.
Ethical approval was obtained from the ethical review 
committee of Aga Khan University Karachi (ERC number 
2020-1563-14158) and the National Bioethics Committee 
of Pakistan (4-87/NBC-323/18/551). Written informed 
consent was obtained from one of the parents or legal 
guardians at the time of enrolment into the study.
Outcomes
The outcomes of interest were the development of 
suspected typhoid fever (irrespective of blood culture), 
culture-confirmed S Typhi (irrespective of antimicrobial 
resistance), culture-confirmed XDR S Typhi, and non-
XDR S Typhi (sensitive to ceftriaxone with or without 
multidrug resistance or fluoroquinolone resistance, or 
both) among age-eligible unvaccinated children and 
those vaccinated with a single dose of Typbar-TCV.
Statistical analysis
We analysed data using Stata, version 15. The vaccinated 
cohort and quality control cohort were merged with 
the surveillance records for this analysis. Since the vacci-
nation campaign and baseline registration of households 
occurred on the same day in each neighbourhood, the 
person-time at risk for each child was calculated from 
the date of vaccination (for vaccinated children) or the 
date of baseline registration (for unvaccinated children) 
to the date of suspected typhoid fever or culture-
confirmed S Typhi (for children with an outcome) or the 
end of study follow-up (Dec 31, 2019) or death or loss to 
follow-up, whichever occurred first. Incidence rates with 
their corresponding incidence rate ratio (IRR) and 
95% CIs were calculated. We excluded any cases of 
typhoid fever that occurred less than 28 days after 
vaccination from the calculation of vaccine effectiveness. 
Vaccine effectiveness, with 95% CIs, against culture-
confirmed, culture-negative suspected, and XDR S Typhi 
was calculated as follows: 100 × (1–IRR). Cox regression 
analysis was done to measure the hazard ratio (HR) of 
developing culture-confirmed S Typhi when adjusted for 
age, sex, and residential area. Kaplan-Meier curves 
were also plotted to compare the risk of developing 
culture-confirmed S Typhi among vaccinated versus 
unvaccinated children, children aged 6–59 months 
versus those aged 60–120 months, children living in 
Latifabad versus those living in Qasimabad, and being 
male versus female. Two-sided p values were calculated 
with the log-rank test to estimate statistically significant 
differences between the Kaplan-Meier curves for each 
variable. We measured the impact of Typbar-TCV by 
calculating the differences in quarterly cumulative 
incidence of culture-confirmed S Typhi before (2017) 
and following (2018–19) the vacci nation campaign. No 
imputation was done for missing information, and 









Surveillance registry 216 (1·6%) 2043 (20·5%) 2259 (9·7%)
Case cohort 12 162 (90·5%) 7928 (79·5%) 20 090 (85·8%)
Vaccinated subcohort 1058 (7·9%) ·· 1058 (4·5%)
Area of residence in Hyderabad, Pakistan
Qasimabad 5382 (40·1%) 4330 (43·4%) 9712 (41·5%)
Latifabad 8054 (59·9%) 5641 (56·6%) 13 695 (58·5%)
Sex 
Male 7010 (52·2%) 5204 (52·2%) 12 214 (52·2%)
Female 6426 (47·8%) 4767 (47·8%) 11 193 (47·8%)
Age groups
6–59 months 5521 (41·1%) 4647 (46·6%) 10 168 (43·4%)
60–120 months 7915 (58·9%) 5314 (53·4%) 13 239 (56·6%)
Overall typhoid fever cases 1969 (14·7%) 3409 (34·2%) 5378 (23·0%)
Blood culture tests (n=5378)
Yes 320/1969 (16·3%) 2176/3409 (63·8%) 2496/5378 (46·4%)
No 1649/1969 (83·7%) 1233/3409 (36·2%) 2882/5378 (53·6%)
Blood culture result (n=2496)
Negative 273/320 (85·3%) 1448/2176 (66·5%) 1721/2496 (69·0%)
Positive for S Typhi 47/320 (14·7%) 728/2176 (33·5%) 775/2496 (31·0%)
XDR status (n=775)
Non-XDR 6/47 (12·8%) 205/728 (28·2%) 211/775 (27·2%)
XDR 18/47 (38·3%) 426/728 (58·5%) 444/775 (57·3%)
Results not known 23/47 (48·9%) 97/728 (13·3%) 120/775 (15·5%)
Data are n (%) or n/N (%). S Typhi=Salmonella enterica serotype Typhi. XDR=extensively drug-resistant. 
Table 1: Descriptive characteristics of participants included in vaccine effectiveness analysis (n=23 407)
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The sample size was calculated with OpenEpi, version 3, 
for cohort design. Assuming the incidence of culture-
confirmed S Typhi among unvaccinated children aged 
6 months to 15 years is 455 per 100 000,3 and assuming 
50% vaccine coverage, in order to detect a vaccine 
effectiveness of at least 55% against culture-confirmed 
S Typhi8 with 80% power and 95% CIs, using the χ² test 
with continuity correction and after adjusting for a non-
response rate of 15%, the required minimum sample size 
was 20 847 for the quality control cohort. We did not do 
any sample size calculation for the subset of the vaccinated 
cohort for continuous fortnightly follow-ups. The vacci-
nated subcohort was arbitrarily selected primarily for 
immunogenicity assessment at several timepoints and 
periodically followed up for ascertainment of an outcome.
Role of the funding source
The funder of the study had no role in study design, data 









time at risk, 
years*
S Typhi incidence; number of cases 
per 100 000 population (95% CI)
S Typhi incidence; number of 
cases per 100 000 person-years 
(95% CI)
S Typhi incidence 
rate ratio (95% CI) 
Vaccine effectiveness* 
(95% CI)
Both culture-confirmed and suspected S Typhi cases
Age 6–59 months
Vaccinated 940 5521 8646 17 025·9 (16 034·4–18 017·4) 10 872·2 (10 643·0–11 101·3) 0·50 (0·46–0·54) 50·0 (45·8–53·9)
Unvaccinated 1653 4647 7599 35 571·3 (34 194·9–36 947·8) 21 752·1 (21 263·0–22 241·1) ·· ··
Age ≥5 years
Vaccinated 1029 7915 12103 13 000·6 (12 259·7–13 741·5) 8502·2 (8350·7–8653·6) 0·42 (0·39–0·46) 57·8 (54·4–60·9)
Unvaccinated 1756 5324 8722 32 982·7 (31 719·8–34 245·6) 20 132·0 (19 709·5–20 554·5) ·· ··
Overall
Vaccinated 1969 13436 20749 14 654·7 (14 056·7–15 252·7) 9489·7 (9360·6–9618·9) 0·45 (0·43–0·48) 54·6 (52·0–57·0)
Unvaccinated 3409 9971 16322 34 189·1 (33 258·1–35 120·2) 20 886·3 (20 565·9–21 206·7) ·· ··
Suspected typhoid fever cases
Age 6–59 months
Vaccinated 918 5521 8646 16 627·4 (15 645·3–17 609·6) 10 617·7 (10 393·9–10 841·5) 0·62 (0·57–0·67) 38·1 (32·6–43·2)
Unvaccinated 1304 4647 7599 28 061·1 (26 769·3–29 352·9) 171 59·5 (16 773·7–17 545·3) ·· ··
Age ≥5 years
Vaccinated 1004 7915 12 103 12 684·8 (11951·6–13 418·0) 8295·6 (8147·8–8443·4) 0·53 (0·48–0·57) 47·5 (43·0–51·6)
Unvaccinated 1377 5324 8722 25 864·0 (24 687·8–27 040·3) 15 786·9 (15 455·6–16 118·2) ·· ··
Overall
Vaccinated 1922 13 436 20 749 14 304·9 (13 712·8–14 896·9) 9263·2 (9137·2–9389·2) 0·56 (0·53–0·60) 43·6 (40·2–46·8)
Unvaccinated 2681 9971 16 322 26 888·0 (26 017·7–27 758·3) 16 426·0 (16 174·0–16 678·0) ·· ··
Culture-confirmed S Typhi cases
Age 6–59 months 
Vaccinated 22 5521 8646 398·5 (232·3–564·7) 254·5 (249·1–259·8) 0·06 (0·03–0·09) 94·5 (91·5–96·6)
Unvaccinated 349 4647 7599 7510·2 (6752·4–8268·0) 4592·5 (4489·3–4695·8) ·· ··
Age ≥5 years
Vaccinated 25 7915 12 103 315·9 (192·2–439·5) 206·6 (202·9–210·2) 0·05 (0·03–0·07) 95·2 (92·9–97·0)
Unvaccinated 379 5324 8722 7118·7 (6428·0–7809·4) 4345·1 (4253·9–4436·3) ·· ··
Overall
Vaccinated 47 13436 20 749 349·8 (250·0–449·6) 226·5 (223·4–229·6) 0·05 (0·04–0·07) 94·9 (93·2–96·3)
Unvaccinated 728 9971 16 322 7301·2 (6790·5–7811·8) 4460·3 (4391·9–4528·8) ·· ··
XDR S Typhi cases
Age 6–59 months
Vaccinated 14 5521 8646 253·6 (120·9–386·2) 161·9 (158·5–165·3) 0·06 (0·03–0·10) 94·4 (90·4–97·0)
Unvaccinated 220 4647 7599 4734·2 (4123·6–5344·8) 2895·0 (2829·9–2960·1) ·· ··
Age ≥5 years
Vaccinated 4 7915 12 103 50·5 (1·0–100·1) 33·1 (32·5–33·6)  0·01 (0·00–0·04) 98·6 (96·4–99·6)
Unvaccinated 206 5324 8722 3869·3 (3351·2–4387·3) 2361·7 (2312·2–2411·3) ·· ··
Overall
Vaccinated 18 13 436 20 749 134·0 (72·1–195·8) 86·8 (85·6–87·9) 0·03 (0·02–0·05) 96·7 (94·7–98·0)
Unvaccinated 426 9971 16 322 4272·4 (3875·4–4669·3) 2610·0 (2570·0–2650·1) ·· ··
(Table 2 continues on next page)
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Results
24 206 children from the census registry and surveillance 
system were selected for this study; after removing 
799 (3·3%) non-responders, 23 407 children were included 
in the vaccine effectiveness analysis (figure 1). Of these 
23 407 children, 13 436 (57·4%) were vaccinated with 
Typbar-TCV (table 1). The Latifabad subdistrict accounted 
for 13 695 (58·5%) of children included in the study and 
the remainder were from Qasimabad. 12 214 (52·2%) 
children were male, and 10 168 (43·4%) were aged 
6–59 months. 5378 (23·0%) of 23 407 children were 
identified to have suspected typhoid fever, of whom 
2496 (46·4%) were tested for blood culture and 775 (31·0%) 
of 2496 were positive for S Typhi. Information about 
antimicrobial sensitivity was available for 655 (84·5%) of 
these 775 children, of whom 444 (57·3%) had XDR S Typhi.
Overall, the incidence of suspected typhoid fever was 
9490 (95% CI 9361–9619) per 100 000 person-years 
among vaccinated children and 20 886 (20 566–21 207) 
per 100 000 person-years among unvaccinated children. 
The IRRs comparing vaccinated and unvaccinated 
children with suspected (regardless of culture) S Typhi, 
culture-negative suspected S Typhi, culture-confirmed 
S Typhi, XDR S Typhi, and non-XDR S Typhi are shown 
in table 2. Vaccine effectiveness was 55% (95% CI 52–57) 
against suspected S Typhi (regardless of culture), 
44% (40–47) against culture-negative suspected S Typhi, 
95% (93–96) against culture-confirmed S Typhi, 
97% (95–98) against XDR S Typhi, and 98% (95–99) 
against non-XDR S Typhi.
The HR of culture-confirmed S Typhi among vaccinated 
children versus unvaccinated children, adjusted for age, 
sex, and area of residence, was 0·05 (95% CI 0·04–0·07; 
p<0·0001; table 3). Kaplan-Meier plots also showed a 
significantly lower risk of culture-confirmed S Typhi 
among vaccinated children than among unvaccinated 
children (p<0·0001), in children aged 60–120 months 
than in those aged 6–59 months (p=0·028), in children 
living in Latifabad versus those living in Qasimabad 
(p=0·016), and in girls versus boys (p=0·044; figure 2).
Throughout the epidemic (2017–19), the highest 
number of non-XDR S Typhi cases was reported in 2017, 
followed by a decline in 2018 and then another rise 
during July–August, 2019 (appendix p 2). The interrupted 
time-series plot of XDR and non-XDR S Typhi cases 
showed a slight decline in 2019 compared to 2017 (before 
the intervention; appendix p 3). Overall, we observed a 
significant decline in cumulative incidence between 
2017 (the reference period) and 2018, and between 2017 
and 2019, except during October–December in 2017–19, 
when a significant rise in incidence was observed 
(appendix p 4).
Discussion
As Typbar-TCV was prequalified by WHO in 








time at risk, 
years*
S Typhi incidence; number of cases 
per 100 000 population (95% CI)
S Typhi incidence; number of 
cases per 100 000 person-years 
(95% CI)
S Typhi incidence 
rate ratio (95% CI) 
Vaccine effectiveness* 
(95% CI)
(Continued from previous page)
Non-XDR  S Typhi cases
Age 6–59 months
Vaccinated 2 5521 8646 36·2 (-14·0–86·4) 23·1 (22·6–23·6) 0·02 (0·00–0·07) 98·1 (93·1–99·8)
Unvaccinated 94 4647 7599 2022·8 (1618·0–2427·6) 1237·0 (1209·1–1264·8) ·· ··
Age ≥5 years
Vaccinated 4 7915 12103 50·5 (1·0–100·1) 33·1 (32·5–33·6) 0·03 (0·01–0·07) 97·4 (93·2–99·3)
Unvaccinated 111 5324 8722 2084·9 (1701·1–2468·7) 1272·6 (1245·9–1299·3) ·· ··
Overall
Vaccinated 6 13 436 20 749 44·7 (8·9–80·4) 28·9 (28·5–29·3) 0·02 (0·01–0·05) 97·7 (94·9–99·2)
Unvaccinated 205 9971 16 322 2056·0 (1777·4–2334·5) 1256·0 (1236·7–1275·3) ·· ··
IRR=incidence rate ratio. S Typhi=Salmonella enterica serotype Typhi. XDR=extensively drug resistant. *Calculated as follows: (1 – IRR) × 100.
Table 2: Distribution of vaccination status and vaccine effectiveness against S Typhi
Univariable hazard 
ratio (95% CI)




Vaccinated 0·05 (0·04–0·07) <0·0001 0·05 (0·04–0·07) <0·0001
Unvaccinated 1 (ref) ·· 1 (ref) ··
Age groups
6–59 months 1·17 (1·02–1·35) 0·028 1·07 (0·93–1·23) 0·346
60–120 months 1 (ref) ·· 1 (ref) ··
Sex
Male 1·16 (1·004–1·33) 0·044 1·15 (1–1·33) 0·050
Female 1 (ref) ·· 1 (ref) ··
Area of residence in Hyderabad, Pakistan
Qasimabad 0·84 (0·73–0·97) 0·014 0·88 (0·77–1·02)  0·083
Latifabad 1 (ref) ·· 1 (ref) ··
S Typhi=Salmonella enterica serotype Typhi.
Table 3: Univariable and multivariable Cox regression analysis for assessment of culture-confirmed S Typhi
See Online for appendix
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and effectiveness data have not yet been extensively 
reported.
This population-based, large-scale, prospective cohort 
study, done in a setting with an ongoing XDR 
S Typhi outbreak, demonstrates the effectiveness of 
Typbar-TCV against culture-confirmed S Typhi. The 
effectiveness of Typbar-TCV was 95% against culture-
confirmed S Typhi and 55% against suspected S Typhi 
(regardless of culture). Vaccine effectiveness against 
XDR S Typhi was 97%. The risk of contracting culture-
confirmed S Typhi was 95% lower among vaccinated 
children than among unvaccinated children. The quarterly 
incidence of S Typhi after the vaccination campaign 
(2018–19) was significantly lower than before the 
vaccination campaign (2017); however, during the last 
quarters of 2018 and 2019, incidence of S Typhi was higher 
than in 2017. The most plausible explanation for the rise 
in cases during this period could be the seasonality 
of S Typhi, as higher numbers of cases—including 
outbreaks—occur during the monsoon period (May to 
September), followed by sporadic cases during the rest of 
the year. Although mass immunisation with Typbar-TCV 
could substantially reduce the number of S Typhi cases 
during the peak monsoon season, we did not observe a 
noticeable decline outside of the peak monsoon season 
in 2018–19. 3-year (2017–19) S Typhi surveillance data 
with the same case definition from the adjacent city 
of Karachi, Pakistan, where mass immunisation with 
Typbar-TCV was not initiated until the end of 2019, 
showed a significantly higher number of S Typhi cases 
in all quarters of 2018–19 compared to 2017,3 further 
demonstrating that the decline in the number of cases 
during the monsoon periods of 2018–19 in Hyderabad, 
Pakistan, was not an artifact of fewer rains or mild 
monsoons during 2018–19 compared to 2017.
Limited data from the use of Typbar-TCV to control 
a typhoid fever outbreak in Zimbabwe reported a 
sharp decline in the number of culture-confirmed and 
Figure 2: Survival analysis of culture-confirmed S Typhi cases
(A) Vaccinated versus unvaccinated children. (B) Children aged 6–59 months versus those aged 60–120 months. (C) Area of residence in Hyderabad, Pakistan 
(Qasimabad vs Latifabad). (D) Male versus female cases. S Typhi=Salmonella enterica serotype Typhi.
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suspected S Typhi cases among children aged 6 months 
to 15 years after 3 months of the vaccination campaign. 
The authors reported culture-confirmed S Typhi in 
21% of cases before the vaccination campaign compared 
to none after vaccination with Typbar-TCV.14 The study 
from Zimbabwe did not report vaccine effectiveness 
or a difference in incidence of S Typhi before and 
after the vaccination campaign and hence cannot 
be compared with our estimates. Furthermore, the 
number of culture-confirmed S Typhi cases reported 
from Zimbabwe was small (23 of 109 blood cultures 
before the immunisation campaign and 0 of 24 blood 
cultures afterwards), whereas in the present study 
we established sentinel and laboratory surveillance, 
and thousands of blood cultures were done to identify 
culture-confirmed S Typhi. In the phase 3 randomised 
controlled trial in Nepal, 20 019 children aged 6 months 
to 16 years were enrolled and randomly assigned 
to receive either a single dose of Typbar-TCV or the 
meningococcal A vaccine; preliminary data reported a 
1-year protective efficacy of TCV of 81·6% (95% CI 
58·8–91·8) against culture-confirmed S Typhi.8 When 
restricting the analysis to S Typhi cases confirmed by 
blood culture among participants who presented with 
fever for at least 3 days before blood culture testing, 
the 1-year protective efficacy further increased to 85·1% 
(95% CI 49·7–95·6). These results are consistent with 
our findings from Hyderabad, Pakistan, where the case 
definition included 3 days of fever before blood culture 
testing and positivity for S Typhi. Likewise, data from a 
double-blind, randomised, placebo-controlled trial of 
children aged 2–5 years in Vietnam reported that two 
doses of another typhoid conjugate vaccine (Vi bound 
to non-toxic recombinant Pseudomonas aeruginosa 
exotoxin A) had a protective efficacy of 91·5% (95% CI 
77·1–96·6) against culture-confirmed S Typhi for 
27 months.15 By contrast, a single-centre, phase 2b trial 
based on an established human challenge model in the 
UK enrolled 112 healthy volunteers aged 18–60 years 
with no history of typhoid fever, typhoid vaccination, or 
prolonged exposure in a typhoid-fever-endemic region, 
and participants were either adminis tered Typbar-TCV, 
the Vi-polysaccharide vaccine, or the meningococcal 
conjugate vaccine (control group); 1 month after vaccine 
administration, all participants were exposed to S Typhi 
via oral ingestion and closely assessed for the 
development of typhoid fever (persistent fever ≥38°C 
for at least 12 h or S Typhi bacteraemia). Based on this 
study, Typbar-TCV was reported to have an effectiveness 
of only 55% (95% CI 27–72).7 The potential explanation 
for the relatively lower efficacy of Typbar-TCV in the 
human challenge study done in the UK could be the 
enrolment of adult participants from a non-endemic 
setting without previous exposure to S Typhi and 
applying a more sensitive case definition (including 
S Typhi bacteraemia with or without clinical 
manifestations), which might not be detectable in an 
endemic setting. Another explanation for the low efficacy 
could be the high challenge dose administered after the 
neutrali sation of gastric acid.
Although the findings of the phase 3 trial of Typbar-TCV 
in Nepal have been reported,8 our study demonstrates 
the real-world effectiveness of the vaccine in the context 
of an outbreak response in an urban, low-income to 
middle-income, typhoid-endemic setting. And although 
the internal validity of randomised controlled trials is 
important, the generalisability of the findings beyond the 
study population is always debatable.16 Furthermore, the 
confidence interval of the reported vaccine efficacy in the 
randomised controlled trial done in Nepal was quite 
wide, suggesting either low power of the study or a fewer 
number of cases than expected. By contrast, our cohort 
study in Hyderabad, Pakistan, was sufficiently powered 
and thus our findings have greater generalisability and 
policy implications. This study is also, to the best of our 
knowledge, the first to report the impact of Typbar-TCV 
against XDR S Typhi.
Key strengths of our study include the use of a cohort 
study design, establishment of a baseline population 
census registry, a tight surveillance system, uniform case 
definition for confirmed and suspected cases, and a large 
sample size, all of which increase not only the internal 
but also external validity of our findings. Moreover, to our 
knowledge this is the first study to report the effectiveness 
of Typbar-TCV in children as young as 6 months.
This study provides important evidence that has impli-
cations for vaccination campaigns to control typhoid fever 
outbreaks. Furthermore, although Pakistan has sub-
optimal vaccination coverage for routine immunisation,17 
the fact that this study showed a vaccine effectiveness 
of more than 90% with a modest coverage of 57% 
is reassuring for Pakistan and other countries facing 
similar challenges relating to routine immunisation. 
Furthermore, this study was done in an outbreak setting 
where the predominant strain type was XDR, indicating 
that Typbar-TCV can help counter antimicrobial resistance 
and is presumably expected to have a concomitant impact 
on mortality from typhoid fever as well.
This study had several limitations. First, clinicians 
only started using blood culture as a diagnostic tool for 
typhoid fever instead of serology in the face of the 
XDR S Typhi outbreak, leading to ascertainment of a 
higher number of culture-confirmed S Typhi cases, and 
hence the change from serology-based to blood-culture-
based diagnoses happened gradually, especially at the 
start of the vaccination campaign, so our impact 
assessment (comparing the incidence of S Typhi before 
and after vaccination) might have been biased towards 
the null, resulting in underestimation of the impact of 
Typbar-TCV. Second, attendance for blood culture was 
much lower among vaccinated than among unvaccinated 
children. This is likely to be due to a vaccine-induced 
reduction in disease burden, but it is plausible that 
vaccination itself might confer improved confidence 
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in wellbeing and reduced treatment-seeking behaviour. 
To mitigate this possibility, we enrolled children inde-
pendently through the surveillance system without 
ascertainment of their vaccination status at the time of 
enrolment, provided a free-of-cost blood testing facility 
for everyone who fulfilled the suspected case definition, 
and involved the data management team to electronically 
link vaccination records. Last, XDR status was unknown 
for 48·9% of the vaccinated culture-confirmed S Typhi 
cases, compared to 13·3% of unvaccinated cases. This 
differential misclassification of unknown XDR status 
(although unknown data were excluded during the 
analysis) has the potential to bias our vaccine effectiveness 
estimates against XDR S Typhi away from the null.
In conclusion, Typbar-TCV was effective against 
culture-confirmed S Typhi among children aged 6 months 
to 10 years in an outbreak setting in Pakistan and was 
able, with only moderate deployment, to curtail a major 
XDR S Typhi outbreak in a densely populated setting. 
Our findings show that the vaccine is effective against 
S Typhi irrespective of antimicrobial resistance.
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